ASSESMENT OF CLINICAL EFFECTIVENESS OF LOSARTAN AND AMLODIPINE IN HYPERTENSIVE PATIENT WITH LEFT VENTRICULAR HYPERTROPHY
Objective: Hypertension is an important worldwide public health challenge because of its high frequency and concomitant risks of cardiovascular and kidney diseases. Left ventricular hypertrophy (LVH) is defined as an increase in the mass of the LV, which can be secondary to an increase in wall thickness, an increase in cavity size, or both. Relevant study reported that LVH is one of the major and independent risk factors for coronary artery disease, heart failure, serious dysrhythmias, and sudden death. Thus, regression of LVH is a primary pharmacologic objective. The objective of this study is to assess the effectiveness of losartan and amlodipine in regression of LVH and to monitor the adverse effects of these drugs on monotherapy. The study also focused to estimate the clinical effectiveness of specified drugs in lowering hypertension.
Methods: The study conducted was retrospective, prospective, comparative study extended over 1 year on 28 patients based on inclusion and exclusion criteria.
Results: Both these drugs cause regression of LVH with a decrease in LV mass index value; it is seen that amlodipine is better in controlling elevated blood pressure (BP), especially diastolic BP. In statistical analysis, regression of LVH was found to be correlated with reduction of BP.
Conclusion: Incidence of adverse effect was found to be prominent in amlodipine group. Thus, losartan was found to be better in regressing LVH than amlodipine.
2. Acharya PV. Irreparable DNA damage by industrial pollutants in pre mature ageing chemical carcinogenesis and cardiac hypertrophy experiments and theory. Isr J Med Sci 1987;13:440-2.
3. Mann DL, Bristow MR. Mechanisms and models in heart failure: The biomechanical model and beyond. Circulation 2005;111(21):2837-49.
4. Kannel WB. Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J 1992;13 Suppl D:82-8.
5. Laufer E, Jennings GL, Korner PI, Dewar E. Prevalence of cardiac structural and functional abnormalities in untreated primary hypertension. Hypertension 1989;13(22):151-62.
6. Beache GM, Herzka DA, Boxerman JL, Post WS, Gupta SN, Faranesh AZ, et al. Attenuated myocardial vasodilator response in patients with hypertensive hypertrophy revealed by oxygenation-dependent magnetic resonance imaging. Circulation 2001;104(11):1213-5.
7. Carluccio E, Tommasi S, Bentivoglio M, Buccolieri M, Filippucci L, Prosciutti L, et al. Prognostic value of left ventricular hypertrophy and geometry in patients with a first, uncomplicated myocardial infarction. Int J Cardiol 2000;74:176-83.
8. Burke AP, Farb A, Liang YH, Smialek J, Virmani R. Effect of hypertension and cardiac hypertrophy on coronary artery morphology in sudden cardiac death. Circulation 1996;94(12):3138-45.
9. Phillips RA. Etiology, pathophysiology, and treatment of left ventricular hypertrophy: Focus on severe hypertension. J Cardiovasc Pharmacol 1993;21 Suppl 2:S55-62.
10. Zou Y, Song L, Wang Z, Ma A, Liu T, Gu H, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: A population- based echocardiographic analysis of 8080 adults. Am J Med 2004;116(1):14-8.
11. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-54.
12. Brink M, Erne P, de Gasparo M, Rogg H, Schmid A, Stulz P, et al. Localization of the angiotensin II receptor subtypes in the human atrium. J Mol Cell Cardiol 1996;28(8):1789-99.
13. Dahlof B, Devereux R, deFaire U, Fyhrquist F, Hedner T, Ibsen H, et al. Baseline characteristics of the LIFE (Losartan intervention for endpoint reduction) in hypertension study. Hypertension 1997;15(4):34-7.
14. Pelliccia A, Maron MS, Maron BJ. Assessment of left ventricular hypertrophy in a trained athlete: Differential diagnosis of physiologic athleteâ€™s heart from pathologic hypertrophy. Prog Cardiovasc Dis 2012;54(5):387-96.
15. ThÃ¼rmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998;98(19):2037-42.
16. Zabalgoitia M. Left ventricular mass and function in primary hypertension. Am J Hypertens 1996;9(8):55s-9.
17. DahlÃ¶f B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992;5(2):95-110.
18. Nalbantgil S, Yilmaz H, Gurun C, Ã–zerkan F, Nalbantgil I, Ã–nder R, et al. Effect of valsartan and enalapril on regression of left ventricular hypertrophy in patients with mild to moderate hypertension. Curr Ther Res 2000;61(6);331-8.
19. Dahlof B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V, et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002;20(9):1855-64.
20. Fogari R, Mugellini A, Destro M, Corradi L, Lazzari P, Zoppi A, et al. Losartan and amlodipine on myocardial structure and function: A prospective, randomized, clinical trial. Diabet Med 2012;29(1):24-31.
21. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990;322(22):1561-6.
22. Shetty K, Shetty R, Rao P, Vivek G, Naveenchandran GS, Razak A, et al. Evaluation of causative factors in amlodipine induced pedal edema. Indian J Pharm Pharm Sci 2016;8(11):303-6.
23. Rosendorff C, Dubiel R, Xu J, Chavanu KJ. Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy. Am J Cardiol 2009;104(3):359-65.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.